Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: Long term results of the EORTC CLG 58881 trial. (2008)
UYTTEBROECK, A,
SUCIU, S,
Laureys, Genevieve,
PAQUEMENT, H,
FERSTER, A,
MARGUERITTE, G,
...
Improved outcome with pulses of Vincristine (VCR) and Steroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and Non Hodgkin Lymphoma (NHL): final report of the EORTC randomized phase III trial 58951 (2008)
De Moerloose, Barbara,
Suciu, S.,
Bertrand, Y.,
Mazingue, F.,
Robert, A.,
Uyttebroeck, A.,
...
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study (2007)
Hasle, H.,
Alonzo, T.A.,
Auvrignon, A.,
Behar, C.,
Chang, M.,
Creutzig, U.,
...
Monosomy 7 (-7) and deletion 7q [del(7q)] are rare in childhood acute myeloid leukemia (AML). We retrospectively collected data on 258 children with AML or refractory anemia with excess blasts in...
Stem cell transplantation in ALL : a donor versus no donor comparison in the EORTC ALL-4 study (2007)
Labar, B.,
Suciu, S.,
Muus, P.,
Willemze, R.,
Marie, J.P.,
Fillet, Georges,
...
Prognostic significance of blasts with/without pleiocytosis in the cerebro-spinal fluid (CSF) of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) children leukemia group study 58881 (2006)
Sirvent, N,
Suciu, S,
Rialland, X,
Robert, A,
Mazingue, F,
Millot, F,
...
Non-infusional vs intravenous consolidation chemotherapy in eldery patients with acute myeloid leukemia : final results of th EORTC-GIMAMA AML-13 randomized phase III trial (2006)
Jehn, U.,
Suciu, S.,
Thomas, X.,
Lefrère, F.,
Muus, P.,
Berneman, Zwi,
...
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report (2005)
ENTZ-WERLE, N,
SUCIU, S,
TEN BOSCH, JD,
VILMER, E,
BERTRAND, Y,
Benoit, Yves,
...
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951 (2004)
CAVÉ, H,
SUCIU, S,
PREUDHOMME, C,
Poppe, Bruce,
ROBERT, A,
UYTTEBROECK, A,
...
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921) (2003)
Suciu, S,
Labar, B,
Belhabri, A,
Aul, C,
...
This report used the framework of a large European study to investigate the outcome of patients with and without an HLA-identical sibling donor on an intention-to-treat basis. After a common...
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial (2003)
Keating, S,
Suciu, S,
De Witte, T,
Zittoun, R,
Mandelli, F,
Belhabri, A,
...
Variable numbers of CD34(+) cells can be harvested from the blood of AML patients in CR after G-CSF supported mobilization following consolidation chemotherapy. We hypothesized that a decreased...
Statistical methodology of phase III cancer clinical trials: advance and future perspectives (2002)
SYLVESTER, Richard,
LEGRAND, Catherine,
DECLERCK, Lieven,
Van Glabbeke, M.,
Collette, L.,
Suciu, S.,
...
Statistical methodology of phase III cancer clinical trials: advance and future perspectives (2002)
SYLVESTER, Richard,
LEGRAND, Catherine,
DECLERCK, Lieven,
Van Glabbeke, M.,
Collette, L.,
Suciu, S.,
...
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer - Children's Leukemia Group phase 3 trial. (2002)
DUVAL, M,
SUCIU, S,
FERSTER, A,
RIALLAND, X,
NELKEN, B,
LUTZ, P,
...
HOX11L2 expression linked to t(5;14)(q35;q32) is not associated with poor prognosis in childhood T-ALL treated in EORTC trials 58 881 and 58 951 (2002)
CAVÉ, H,
SUCIU, S,
PREUDHOMME, C,
Poppe, Bruce,
ROBERT, A,
UYTTEBROEK, A,
...
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914) (2001)
Sonneveld, P.,
Suciu, S.,
Weijermans, P.,
Beksac, M.,
Neuwirtova, R.,
Solbu, G.,
...
Treatment of childhood T-cell lymphoblastic non-Hodgkin lymphoma according to the strategy for acute lymphoblastic leukemia: Long-term results of the EORTC 58881 trial (2001)
UYTTEBROECK, A,
SUCIU, S,
BERTRAND, Y,
Laureys, Genevieve,
ROBERT, A,
PACQUEMENT, H,
...
Treatment outcome in infant acute lymphoblastic leukemia. (2000)
FERSTER, A,
Benoit, Yves,
FRANCOTTE, N,
DRESSE, MF,
UYTTEBROECK, A,
PLOUVIER, E,
...
Long-term results of three randomized trials (58831,58832,58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. (2000)
VILMER, E,
SUCIU, S,
FERSTER, A,
BERTRAND, Y,
CAVÉ, H,
THYSS, A,
...
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial. (2000)
MILLOT, F,
SUCIU, S,
PHILIPPE, N,
Benoit, Yves,
MAZINGUE, F,
UYTTEBROECK, A,
...
Pentostatin in T-cell malignancies - a phase II trial of the EORTC (1999)
Ho, A. D.,
Suciu, S.,
Stryckmans, P.,
De Cataldo, F.,
Willemze, R.,
Thaler, J.,
...
Purpose: Within this phase II EORTC trial, we have investigated the safety and efficacy of pentostatin in lymphoid malignancies. We have previously reported the results in T-and B-cell prolymphocytic...
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy: the value of low-dose cytarabine for maintenance of remission and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report (1998)
Lowenberg, B.,
Suciu, S.,
Archimbaud, E.,
Haak, H.,
Stryckmans, P.,
Cataldo, R. De,
...
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy: the value of low-dose cytarabine for maintenance of remission and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report (1998)
Lowenberg, B.,
Suciu, S.,
Archimbaud, E.,
Haak, H.,
Stryckmans, P.,
Cataldo, R. De,
...
Mitoxantrone Versus Daunorubicin in Induction-Consolidation Chemotherapy - The Value of Low-Dose Cytarabine for Maintenance of Remission, and an Assessment of Prognostic Factors in Acute Myeloid Leukemia in the Elderly : Final Report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and th Dutch-Belgian Hemato-Oncology Cooperative Hovon Group Randomized Phase III Study AML-9 (1998)
Löwenberg, B.,
Suciu, S.,
Archimbaud, E.,
Haak, H.,
Stryckmans, P.,
De Cataldo, R.,
...
Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial (1997)
Willemze, R.,
Dardenne, M.,
Resegotti, L.,
Thaler, J.,
Peetermans, M.,
Stryckmans, P.,
...
Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the research and treatment of cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON) (1997)
Zittoun, R.,
Dardenne, M.,
Sonneveld, P.,
Muus, P.,
Jehn, U.,
Schouten, H.C.,
...
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893) (1997)
Zittoun, R.,
Dardenne, M.,
Jaksic, B.,
Labar, B.,
Jehn, U.,
Dohner, H.,
...
Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial (1996)
Zittoun, R.,
Vegna, M.L.,
Solbu, G.,
Dardenne, M.,
Petti, M.C.,
Muus, P.,
...
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (06901) of the EORTC Leukemia Cooperative Group (1996)
Muus, P.,
Solbu, G.,
Dardenne, M.,
Hayat, M.,
Kurstjens, R.,
Ribeiro, M.,
...
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for research and treatment of cancer leukemia cooperative group (1996)
Willemze, R.,
Petti, M.C.,
Solbu, G.,
Cadiou, M.,
Peetermans, M.,
Hayat, M.,
...
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration : a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG) (1995)
Muus, P.,
Zwierzina, H.,
Solbu, G.,
Dardenne, M.,
Zittoun, R.,
Selleslag, S.,
...
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia (1995)
Suciu, S.,
Solbu, G.,
Petti, M.C.,
Vegna, M.L.,
Dardenne, M.,
Peetermans, M.E.,
...
Systemic Effect of Intrahepatic Methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 1997, 15 : 1824-1830.
THYSS, A,
SUCIU, S,
BERTRAND, Y,
MAZINGUE, F,
ROBERT, A,
VILMER, E,
...
High tPA-expression in primary melanoma of the limb correlates with good prognosis
Ferrier, C M,
Suciu, S,
Van Geloof, W L,
Straatman, H,
Eggermont, A M M,
Koops, H Schraffordt,
...
To investigate whether the course of primary melanoma disease correlates with expression of the various components of the proteolytic plasminogen activation (PA) system, immunohistochemical stainings...